Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases
B. Vergier(Centre Hospitalier Universitaire de Bordeaux), Jean‐Philippe Merlio(Hôpital Cardiologique du Haut-Lévêque), Martina Prochazkova‐Carlotti(Hôpital Cardiologique du Haut-Lévêque), Apollon Karlseladze(Russian Cancer Research Center NN Blokhin), Thomas Jouary(Hôpital Saint-André), Arnaud de la Fouchardière(Université Claude Bernard Lyon 1), Lorenzo Cerroni(Medical University of Graz), Marie‐Françoise Avril(Délégation Paris 7), Ulrich Wesselmann(Witten/Herdecke University), Vincenzo De Giorgi(Istituto di Chimica Biomolecolare), Christiane Bailly(Centre Léon Bérard), Daniela Massi(University of Florence)
Cited by 140
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
Germline mutations in BAP1 predispose to melanocytic tumors
|Nature Genetics|2011|724